Black Diamond Therapeutics, Inc. financial data

Symbol
BDTX on Nasdaq
Location
One Main Street, 14 Th Floor, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 778 % +19%
Debt-to-equity 28.8 % -22.4%
Return On Equity 17.8 %
Return On Assets 13.8 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 57M shares +0.69%
Common Stock, Shares, Outstanding 56.9M shares +0.75%
Entity Public Float 210M USD +83.5%
Common Stock, Value, Issued 8K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 56.9M shares +0.75%
Weighted Average Number of Shares Outstanding, Diluted 56.9M shares +0.75%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 39.6M USD -27.2%
General and Administrative Expense 18.6M USD -31.3%
Operating Income (Loss) 11.9M USD +39.4%
Nonoperating Income (Expense) 9.64M USD +16.7%
Income Tax Expense (Benefit) 226K USD
Net Income (Loss) Attributable to Parent 21.5M USD +45.4%
Earnings Per Share, Basic 0 USD/shares +46.4%
Earnings Per Share, Diluted 0 USD/shares +46.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 30.9M USD +31.8%
Assets, Current 139M USD +20.3%
Property, Plant and Equipment, Net 1.13M USD -23.4%
Operating Lease, Right-of-Use Asset 16.7M USD -15.7%
Other Assets, Noncurrent 117K USD -60.1%
Assets 158M USD +14.4%
Accounts Payable, Current 975K USD -50.5%
Employee-related Liabilities, Current 2.37M USD -44.3%
Accrued Liabilities, Current 14.6M USD -22.6%
Liabilities, Current 15.5M USD -25.3%
Operating Lease, Liability, Noncurrent 16M USD -18.5%
Liabilities 31.6M USD -22%
Accumulated Other Comprehensive Income (Loss), Net of Tax 142K USD +32.7%
Retained Earnings (Accumulated Deficit) -450M USD +4.56%
Stockholders' Equity Attributable to Parent 126M USD +29.5%
Liabilities and Equity 158M USD +14.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 53.4M USD
Net Cash Provided by (Used in) Financing Activities 32K USD -99.2%
Net Cash Provided by (Used in) Investing Activities 8.55M USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 56.9M shares +0.75%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 62M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 31.7M USD +30.7%
Deferred Tax Assets, Valuation Allowance 128M USD +15.2%
Deferred Tax Assets, Gross 132M USD +13.3%
Operating Lease, Liability 22.2M USD -12.3%
Depreciation 87K USD +1.16%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 21.5M USD +45.7%
Lessee, Operating Lease, Liability, to be Paid 26.1M USD -14.3%
Property, Plant and Equipment, Gross 2.53M USD 0%
Operating Lease, Liability, Current 3.63M USD +9.16%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.6M USD +2.73%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.48M USD +2.71%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.87M USD -24.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.72M USD +2.72%
Deferred Tax Assets, Operating Loss Carryforwards 78.9M USD +14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.93M USD -16.9%
Operating Lease, Payments 1.11M USD +2.69%
Additional Paid in Capital 576M USD +1.27%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 4.65M USD -21.7%
Share-based Payment Arrangement, Expense 6.85M USD -34.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%